一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Nemtabrutinib；Ibrutinib；Acalabrutinib，当前状态为招募中。登记地点显示中国合肥、北京、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Nemtabrutinib；Ibrutinib；Acalabrutinib · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 2001) · 合肥
- Peking University First Hospital ( Site 2022) · 北京
- Peking University Third Hospital-Hematology ( Site 2011) · 北京
- Chongqing University Cancer Hospital ( Site 2041) · 重庆
- Sun Yat-sen University Cancer Center ( Site 2028) · 广州
- Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 2006) · 广州
- Liuzhou People's Hospital ( Site 2029) · 柳州
- Guangxi Medical University Affiliated Tumor Hospital ( Site 2004) · 南宁
- The Affiliated Hospital of Guizhou Medical University ( Site 2024) · 贵阳
- Hainan General Hospital ( Site 2018) · 海口
- Henan Cancer Hospital-hematology department ( Site 2025) · 郑州
- Tongji Hospital Affiliated to Tongji Medical College of HUST ( Site 2016) · 武汉
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2015) · 武汉
- Hunan Cancer Hospital ( Site 2020) · 长沙
- The Second Xiangya Hospital of Central South University ( Site 2010) · 长沙
- Jiangsu Province Hospital ( Site 2000) · 南京
- The First Affliated Hospital of Suzhou University ( Site 2027) · 苏州
- The Affiliated Hospital of Xuzhou Medical College ( Site 2013) · 徐州
- The First Affiliated Hospital of Nanchang University ( Site 2023) · 南昌
- Jiangxi Provincial Cancer Hospital ( Site 2009) · 南昌
- The First Hospital of Jilin University-Hematology ( Site 2030) · 长春
- Shaanxi provincial people's hospital ( Site 2012) · 西安
- Shandong Cancer Hospital ( Site 2003) · 济南
- Shanxi Cancer Hospital ( Site 2033) · 太原
- West China Hospital, Sichuan University-Head and Neck Oncology ( Site 2026) · 成都
- Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 2019) · 天津
- Institute of hematology&blood disease hospital-Lymphoma ( Site 2005) · 天津
- Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2014) · 乌鲁木齐
- The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology ( Site 2002) · 杭州
- Zhejiang Cancer Hospital ( Site 2017) · 杭州
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy.
- * Has at least 1 marker of disease burden.
- * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
- * Has the ability to swallow and retain oral medication.
- * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
- * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
- * Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06136559；登记信息更新于 2026-09-14。